IGM BIOSCIENCES, INC. (IGMS): Price and Financial Metrics
IGMS Price/Volume Stats
| Current price | $12.09 | 52-week high | $28.20 |
| Prev. close | $12.84 | 52-week low | $9.74 |
| Day low | $11.82 | Volume | 90,727 |
| Day high | $12.45 | Avg. volume | 219,358 |
| 50-day MA | $12.37 | Dividend yield | N/A |
| 200-day MA | $18.52 | Market Cap | 520.86M |
IGMS Stock Price Chart Interactive Chart >
IGMS POWR Grades
- Quality is the dimension where IGMS ranks best; there it ranks ahead of 39.78% of US stocks.
- The strongest trend for IGMS is in Sentiment, which has been heading up over the past 179 days.
- IGMS's current lowest rank is in the Stability metric (where it is better than 9.96% of US stocks).
IGMS Stock Summary
- Of note is the ratio of IGM BIOSCIENCES INC's sales and general administrative expense to its total operating expenses; just 8.54% of US stocks have a lower such ratio.
- IGMS's price/sales ratio is 313.86; that's higher than the P/S ratio of 98.76% of US stocks.
- Revenue growth over the past 12 months for IGM BIOSCIENCES INC comes in at 334.7%, a number that bests 97.68% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to IGM BIOSCIENCES INC, a group of peers worth examining would be ARVN, FATE, BEAM, NTLA, and DNLI.
- Visit IGMS's SEC page to see the company's official filings. To visit the company's web site, go to igmbio.com.
IGMS Valuation Summary
- In comparison to the median Healthcare stock, IGMS's price/sales ratio is 14722.73% higher, now standing at 326.1.
- IGMS's EV/EBIT ratio has moved up 29.2 over the prior 45 months.
Below are key valuation metrics over time for IGMS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| IGMS | 2023-05-23 | 326.1 | 2.2 | -2.3 | -1.8 |
| IGMS | 2023-05-22 | 331.5 | 2.2 | -2.3 | -1.9 |
| IGMS | 2023-05-19 | 294.6 | 2.0 | -2.1 | -1.6 |
| IGMS | 2023-05-18 | 306.0 | 2.0 | -2.1 | -1.7 |
| IGMS | 2023-05-17 | 323.1 | 2.1 | -2.2 | -1.8 |
| IGMS | 2023-05-16 | 347.0 | 2.3 | -2.4 | -2.0 |
IGMS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- IGMS has a Quality Grade of D, ranking ahead of 7.29% of graded US stocks.
- IGMS's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows IGMS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0 | NA | -0.989 |
| 2021-06-30 | 0 | NA | -0.807 |
| 2021-03-31 | 0 | NA | -0.567 |
| 2020-12-31 | 0 | NA | -0.435 |
| 2020-09-30 | 0 | NA | -0.350 |
| 2020-06-30 | 0 | NA | -0.345 |
IGMS Price Target
For more insight on analysts targets of IGMS, see our IGMS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $103.00 | Average Broker Recommendation | 1.33 (Strong Buy) |
IGM BIOSCIENCES, INC. (IGMS) Company Bio
IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The company was founded in 2010 and is headquartered in Mountain View, CA.
Latest IGMS News From Around the Web
Below are the latest news stories about IGM BIOSCIENCES INC that investors may wish to consider to help them evaluate IGMS as an investment opportunity.
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Lags Revenue EstimatesIGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 2.92% and 70.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update– Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway – – Plans to present additional non-randomized clinical data for 3 mg/kg of IGM-8444 plus FOLFIRI, with and without bevacizumab, in the middle of 2023 – – Plans to begin clinical testing of imvotamab in severe systemic lupus erythematosus and severe rheumatoid arthritis – MOUNTAIN VIEW, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical- |
IGM Biosciences to Present at Two Upcoming Investor ConferencesMOUNTAIN VIEW, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will present at two upcoming investor conferences: Bank of America Health Care Conference on Tuesday, May 9 at 3:40 p.m. PDT in Las VegasRBC Global Healthcare Conference on Wednesday, May 17 at 11:00 a.m. EDT in New York A live webcast of the events will be available on th |
Bullish IGM Biosciences, Inc. (NASDAQ:IGMS) insiders filled their treasuries with US$1.6m worth of stock over last yearOver the last year, a good number of insiders have significantly increased their holdings in IGM Biosciences, Inc... |
IGM Biosciences to Present at the Stifel 2023 Targeted Oncology DaysMOUNTAIN VIEW, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 3:00 p.m. EDT. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” sec |
IGMS Price Returns
| 1-mo | -2.11% |
| 3-mo | -44.11% |
| 6-mo | -42.21% |
| 1-year | -27.52% |
| 3-year | -80.82% |
| 5-year | N/A |
| YTD | -28.92% |
| 2022 | -42.00% |
| 2021 | -66.78% |
| 2020 | 131.37% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...